Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 570 clinical trials
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements (STARTRK-2)

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

solid tumour
lymphoma
ROS1
cancer treatment
gene fusion
  • 16 views
  • 25 Oct, 2022
  • 9 locations
Personalized PRRT of Neuroendocrine Tumors (P-PRRT)

In this study, peptide receptor radionuclide therapy (PRRT) with 177Lu-Octreotate (LuTate) will be personalized, i.e. administered activity of LuTate will be tailored for each patient to maximize absorbed radiation dose to tumor, while limiting that to healthy organs. The purpose of this study is to: Assess the objective (radiological), symptomatic …

177lu-octreotate
positron emission tomography
radionuclide therapy
peptide receptor radionuclide therapy
somatostatin
  • 91 views
  • 23 Feb, 2022
  • 1 location
Telotristat With Lutathera in Neuroendocrine Tumors

This trial will test the hypothesis that Telotristat treatment increases the antitumor efficacy of Lutetium Lu 177 Dotatate therapy in neuroendocrine tumors (NETs).

  • 0 views
  • 10 Oct, 2021
  • 1 location
Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana)

somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use [68Ga]-DOTA-TATE PET to image epigenetic modification of the receptor locus.

  • 0 views
  • 04 Oct, 2022
  • 1 location
Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors

-68 NODAGA-JR11 for the diagnostic imaging of metastatic, well-differentiated neuroendocrine tumors using positron emission tomography / computed tomography (PET/CT). The results will be

  • 0 views
  • 04 Oct, 2022
  • 2 locations
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

advanced neuroendocrine tumors.

neutrophil count
neuroendocrine tumor
small molecule
cancer
somatostatin
  • 49 views
  • 03 Feb, 2022
  • 7 locations
Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients (ALPHAMEDIX02)

Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy

  • 0 views
  • 22 Mar, 2022
  • 1 location
Biodistribution of Ga-68 Pentixafor in Patients With Neuroendocrine Tumors

This study will evaluate how Gallium-68 Pentixafor is distributed in neuroendocrine tumor patients and if that distribution is consistent through repeated scans. This is an RDRC study

dotatate
somatostatin
pet/ct scan
ct scan
  • 4 views
  • 17 Oct, 2022
  • 1 location
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

The purpose of this study is to explore the efficacy and safety of chidamide combined with sintilimab in chemotherapy-refractory advanced high-grade neuroendocrine neoplasm.

neutrophil count
tumor progression
pd-l1
platelet count
measurable disease
  • 0 views
  • 02 Dec, 2021
  • 2 locations
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

classes of anticancer drugs. APG-1252 is intended for the treatment of patients with neuroendocrine tumors. The purpose of the phase 1b study to establish the maximum tolerated dose (MTD), and/or

  • 0 views
  • 26 Mar, 2022
  • 1 location